ABSTRACT
About Factor IX Deficiency Treatment
The global factor IX deficiency treatment market is characterized by the presence of various therapeutic products provided by some of the top vendors such as Shire, CSL Behring, Novo Nordisk, Biogen, and Pfizer. The adoption rate of therapeutics has undergone a paradigm shift toward the introduction of gene therapy, which will lead to the development of new products. However, the low penetration rate of recombinant therapy in developing countries is the current challenge in the market. This low penetration rate in developing countries is due to the higher cost of recombinant drugs, limited disease knowledge, and a shortage of treatment supplies. Nevertheless, the market has observed a positive side of individuals adopting recombinant drugs is expected to improve the diagnosis and treatment rates for hemophilia B in the medium- to long-term.
Technavio’s analysts forecast the global factor IX deficiency treatment market to grow at a CAGR of 5.12% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global factor IX deficiency treatment market for 2017-2021. To calculate the market size, the report considers the revenue generated from sales of factor IX products in the different diseases.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Factor IX Deficiency Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Biogen
• CSL Behring
• Novo Nordisk
• Pfizer
• Shire
Market driver
• Growing pipeline with increased focus to meet unmet demand.
• For a full, detailed list, view our report
Market challenge
• Emerging price war in the industry.
• For a full, detailed list, view our report
Market trend
• Increase in investments in the production and discovery.
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
• Market overview
• Assumptions
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
• Highlights
PART 05: Disease overview
PART 06: Pipeline analysis
PART 07: Market landscape
• Market overview
• Five forces analysis
PART 08: Market segmentation by disease type
• Global hemophilia B drugs market
• Global hemophilia B inhibitors market
PART 09: Market segmentation by type of therapy
• Recombinant therapies
• Plasma-derived therapies
PART 10: Market segmentation by type of disease management
• Prophylaxis
• On-demand therapy
• Inhibitor therapy
PART 11: Geographical segmentation
• Factor IX drugs market in Americas
• Factor IX drugs market in EMEA
• Factor IX drugs market in APAC
PART 12: Market drivers
• Shifting toward half-life drugs
• Special designations promote novel launches
• Growing pipeline with increased focus to meet unmet demand
PART 13: Impact of drivers
PART 14: Market challenges
• Emerging price war in the industry
• Low penetration rate
• Lack of complete remission
• High entry barriers
PART 15: Impact of drivers and challenges
PART 16: Market trends
• Increasing focus on gene therapy
• Increase in investments in the production and discovery
• Strategic initiatives should lead to consolidation
PART 17: Vendor landscape
• Competitive scenario
PART 18: Key vendor analysis
• Biogen
• CSL Behring
• Novo Nordisk
• Pfizer
• Shire
PART 19: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Process of gene therapy
Exhibit 03: Key buying criteria and customer segments of global factor IX deficiency treatment market
Exhibit 04: Key customer segments of factor IX deficiency treatment market
Exhibit 05: Pipeline analysis
Exhibit 06: Key clinical trials
Exhibit 07: Global factor IX deficiency treatment market snapshot
Exhibit 08: Global factor IX deficiency treatment market by revenue 2016-2021 ($ millions)
Exhibit 09: Five forces analysis
Exhibit 10: Hemophilia B drugs market for global factor IX deficiency treatment market 2016-2021 ($ millions)
Exhibit 11: Hemophilia B inhibitors market for global factor IX deficiency treatment market 2016-2021 ($ millions)
Exhibit 12: Global factor IX recombinant therapies market 2016-2021 ($ millions)
Exhibit 13: Global factor IX plasma-derived therapies market 2016-2021 ($ millions)
Exhibit 14: Segmentation of factor IX drugs market by type of disease management 2016
Exhibit 15: Factor IX deficiency treatment market in Americas 2016-2021 ($ millions)
Exhibit 16: Factor IX deficiency treatment market in EMEA 2016-2021 ($ millions)
Exhibit 17: Factor IX deficiency treatment market in APAC 2016-2021($ millions)
Exhibit 18: Launch of half-life drugs for treatment of factor IX deficiency
Exhibit 19: Special designation to factor IX drugs in 2016
Exhibit 20: A few late-stage (Phase III) factor IX drugs
Exhibit 21: Impact of drivers
Exhibit 22: Impact of drivers and challenges
Exhibit 23: Competitive structure of global factor IX deficiency treatment market 2016
Exhibit 24: Competitive analysis of global factor IX deficiency treatment market
Exhibit 25: Market share analysis 2016
Exhibit 26: Market penetration of factor IX vendors 2016
Exhibit 27: Biogen: Key highlights
Exhibit 28: Biogen: Strength assessment
Exhibit 29: Biogen: Strategy assessment
Exhibit 30: Biogen: Opportunity assessment
Exhibit 31: Year-over-year (YoY) revenue of ALPROLIX 2014-2016 ($ millions)
Exhibit 32: CSL Behring: Key highlights
Exhibit 33: CSL Behring: Strength assessment
Exhibit 34: CSL Behring: Strategy assessment
Exhibit 35: CSL Behring: Opportunity assessment
Exhibit 36: Novo Nordisk: Key highlights
Exhibit 37: Novo Nordisk: Strength assessment
Exhibit 38: Novo Nordisk: Strategy assessment
Exhibit 39: Novo Nordisk: Opportunity assessment
Exhibit 40: Pfizer: Key highlights
Exhibit 41: Pfizer: Strength assessment
Exhibit 42: Pfizer: Strategy assessment
Exhibit 43: Pfizer: Opportunity assessment
Exhibit 44: Shire: Key highlights
Exhibit 45: Shire: Strength assessment
Exhibit 46: Shire: Strategy assessment
Exhibit 47: Shire: Opportunity assessment
Exhibit 48: Shire: YoY revenue comparison of RIXUBIS 2014 and 2015 ($ millions)
